Ranexa is the extended release tablet made from the key ingredient called Ranolazine. The tablets are fully soluble in dichloromethane and methanol as well as scarcely soluble in tetrahydrofuran, ethanol, acetonitrile and acetone; somewhat soluble in ethyl acetate, isopropanol, toluene and ethyl ether; while it is very little soluble in water. Ranexa extended release tablets contain 500 mg of Ranolazine and is designed for oral dosage with film-coating. The inactive ingredients of Ranexa 500 mg extended release tablets include: carnauba wax, hypromellose, magnesium state, and methyl acrylic acid copolymer – type C, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium hydroxide, titanium dioxide as well as FD & C yellow # 6 Lake color.  

Ranexa has anti-anginal and anti-ischemic effects which are not dependent upon decreases in the heart rate or blood pressure levels. The technique of its function is also yet unknown. The drug does not enhance the rate-pressure product, the measure of myocardial work at optimum exercise. 

Ranexa is prepared for the treatment of chronic angina as it continues the QT interval; it should be reserved for the patients who have not received the sufficient reaction with some other anti-anginal drug preparations. It is suggested that the drug should be used in permutation with amlodipine, beta-blocker or nitrates. However, the effect of angina rate as well as exercise forbearance exhibited to be lesser in women as compared to men. Ranexa should be taken with or without meals, but the tablets should never be chewed, crushed or broken instead it should be swallowed intact.